This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mulé, J. J. Articles by Rosenberg, S. A. Search for Related Content PubMed PubMed Citation Articles by Mulé, J. J. Articles by Rosenberg, S. A.

Eradication of a Disseminated Syngeneic Mouse Lymphoma by Systemic Adoptive Transfer of Immune Lymphocytes and Its Dependence upon a Host Component(s)

Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20205

We have studied the in vivo effects of carrageenan and trypan blue on the adoptive immunotherapy of an established local and disseminated syngeneic mouse FBL-3 lymphoma. Mice receiving 500 rads total-body irradiation before injection of FBL-3 tumor into the footpad were treated 4 to 5 days later when a palpable local tumor and disseminated metastases were present. Injection of in vivo immune lymphocytes i.v. caused complete regression of footpad tumor and cured 96% of all mice (>60 days mean survival; p< 0.0005). Carrageenan or trypan blue treatment of the tumor-bearing host abrogated the therapeutic effect of adoptively transferred cells. Cure rates were significantly reduced to 27% (p < 0.004) and 0% (p < 0.0001) and mean survival times to 40.2 days (p < 0.0005) and 15.2 (p < 0.005) days for mice treated with carrageenan and trypan blue, respectively, in addition to immune cells. In vivo treatment of the immune spleen cell donors with carrageenan or trypan blue had no significant effect on the ability of those splenocytes to mediate cure when adoptively transferred into tumor-bearing hosts, indicating that the inhibitory activity of these agents cannot be attributed to direct toxicity to immune lymphoid cells. These results demonstrate that a recipient component(s), possibly macrophages, sensitive to carrageenan and to trypan blue but relatively resistant to radiation (500 rads), plays a vital role in the cure of tumor-bearing mice that receive the adoptive transfer of immune splenocytes.

¹ To whom requests for reprints should be addressed.

Received 6/11/84. Accepted 10/ 3/84.

This article has been cited by other articles:

				H. Nagata, T. Arai, Y. Soejima, H. Suzuki, H. Ishii, and T. Hibi Limited Capability of Regional Lymph Nodes to Eradicate Metastatic Cancer Cells Cancer Res., November 15, 2004; 64(22): 8239 - 8248. [Abstract] [Full Text] [PDF]

				K. Tsung, J. P. Dolan, Y. L. Tsung, and J. A. Norton Macrophages as Effector Cells in Interleukin 12-induced T Cell-dependent Tumor Rejection Cancer Res., September 1, 2002; 62(17): 5069 - 5075. [Abstract] [Full Text] [PDF]

				H. Winter, H.-M. Hu, W. J. Urba, and B. A. Fox Tumor Regression After Adoptive Transfer of Effector T Cells Is Independent of Perforin or Fas Ligand (APO-1L/CD95L) J. Immunol., October 15, 1999; 163(8): 4462 - 4472. [Abstract] [Full Text] [PDF]

				B. I. Rini, L. M. Selk, and N. J. Vogelzang Phase I Study of Direct Intralesional Gene Transfer of HLA-B7 into Metastatic Renal Carcinoma Lesions Clin. Cancer Res., October 1, 1999; 5(10): 2766 - 2772. [Abstract] [Full Text] [PDF]

				M. Nagoshi, P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang, and T. J. Eberlein Successful Adoptive Cellular Immunotherapy Is Dependent on Induction of a Host Immune Response Triggered by Cytokine (IFN-{gamma} and Granulocyte/Macrophage Colony-Stimulating Factor) Producing Donor Tumor-Infiltrating Lymphocytes J. Immunol., January 1, 1998; 160(1): 334 - 344. [Abstract] [Full Text] [PDF]